title: How Ebola-vaccine success could reshape clinical-trial policy.
authors.forename: Declan
authors.initials: D
authors.lastname: Butler
authors.forename: Ewen
authors.initials: E
authors.lastname: Callaway
authors.forename: Erika
authors.initials: E
authors.lastname: Check Hayden
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods* / Q000639:trends*; D016358:Contact Tracing; D004196:Disease Outbreaks / Q000517:prevention & control* / Q000706:statistics & numerical data; D046129:Ebola Vaccines / Q000008:administration & dosage / Q000276:immunology*; D029043:Ebolavirus / Q000276:immunology; D005240:Feasibility Studies; D016701:Guinea / Q000453:epidemiology; D006291:Health Policy / Q000639:trends*; D019142:Hemorrhagic Fever, Ebola / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D006801:Humans; D013997:Time Factors; D016896:Treatment Outcome; D014944:World Health Organization
chemical_list: D046129:Ebola Vaccines